At a Glance
- Company: Bristol Myers Squibb and Hengrui Pharma
- Location: US and China
- Deal value: Up to $15.2 billion
- Focus area: Oncology, haematology and immunology
- Next steps: Close expected in Q3 2026
What happened?
Bristol Myers Squibb and China’s Hengrui Pharma announced a broad strategic alliance covering 13 early-stage drug programmes across oncology, haematology and immunology. BMS will pay $600 million upfront, with additional near-term payments of $175 million on the first and second anniversaries of the deal, and the full package could reach $15.2 billion with milestones and options.
Why does it matter?
The pact gives BMS access to Hengrui’s fast-moving discovery engine and adds multiple shots on goal at a time when major pharma companies are under pressure to refresh pipelines. It also shows how cross-border dealmaking is being used to speed early clinical development and share risk across large, diversified portfolios.
Who’s behind it?
Bristol Myers Squibb will take rights to four Hengrui oncology and haematology assets outside mainland China, Hong Kong and Macau, while Hengrui gains rights to four BMS immunology assets in those territories. The companies will also jointly discover and develop five additional candidates, with Hengrui leading early human development to accelerate proof of concept.
How was it achieved?
The agreement combines upfront cash, staged payments, options and milestones, which is what pushes the headline value to $15.2 billion. The structure also splits regional rights by asset class, giving both companies a way to expand their portfolios while preserving local commercial opportunities.
What’s next?
The companies expect the transaction to be finalised in the third quarter of 2026, after customary regulatory reviews. After that, Hengrui will begin early clinical development on the selected programmes and the partners will advance the jointly discovered assets.